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trials
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Abstract
Background: Appropriately conducted adaptive designs (ADs) offer many potential advantages over conventional
trials. They make better use of accruing data, potentially saving time, trial participants, and limited resources compared
to conventional, fixed sample size designs. However, one can argue that ADs are not implemented as often as they
should be, particularly in publicly funded confirmatory trials. This study explored barriers, concerns, and potential
facilitators to the appropriate use of ADs in confirmatory trials among key stakeholders.
Methods: We conducted three cross-sectional, online parallel surveys between November 2014 and January 2015. The
surveys were based upon findings drawn from in-depth interviews of key research stakeholders, predominantly in the
UK, and targeted Clinical Trials Units (CTUs), public funders, and private sector organisations. Response rates were as
follows: 30(55 %) UK CTUs, 17(68 %) private sector, and 86(41 %) public funders. A Rating Scale Model was used to rank
barriers and concerns in order of perceived importance for prioritisation.
Results: Top-ranked barriers included the lack of bridge funding accessible to UK CTUs to support the design of ADs,
limited practical implementation knowledge, preference for traditional mainstream designs, difficulties in marketing
ADs to key stakeholders, time constraints to support ADs relative to competing priorities, lack of applied training, and
insufficient access to case studies of undertaken ADs to facilitate practical learning and successful implementation.
Associated practical complexities and inadequate data management infrastructure to support ADs were reported as
more pronounced in the private sector. For funders of public research, the inadequate description of the rationale,
scope, and decision-making criteria to guide the planned AD in grant proposals by researchers were all viewed as
major obstacles.
Conclusions: There are still persistent and important perceptions of individual and organisational obstacles hampering
the use of ADs in confirmatory trials research. Stakeholder perceptions about barriers are largely consistent across
sectors, with a few exceptions that reflect differences in organisations’ funding structures, experiences and characterisation
of study interventions. Most barriers appear connected to a lack of practical implementation knowledge and applied
training, and limited access to case studies to facilitate practical learning.
Keywords: Adaptive designs, flexible designs, barriers, surveys, confirmatory trials, Phase 3, clinical trials, early stopping,
interim analyses
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Background
“… there can be no objection to the use of data,
however meagre, as a guide to action required before
more can be collected ….” Thompson, 1933 [1]
The role of clinical trial adaptation has started to come
to the fore in recent years, with numerous methodo-
logical developments over the past 40 years aimed at im-
proving efficiency in the design and conduct of clinical
trials [2, 3]. Researchers and policymakers are now con-
sidering adaptive designs (ADs) more often than before,
and the use of ADs is increasing [4–6]. However, one
could still argue that ADs, particularly in confirmatory
trials, remain underutilised.
Recent research has investigated barriers and oppor-
tunities to the use of ADs, with emphasis on the
pharmaceutical trial perspective [4, 6–8], the US setting
[9, 10], and publicly funded early phase trials in the UK
[11]. Some of these previous studies have been informal
in nature, and some important barriers to successful im-
plementation could potentially have been overlooked.
Furthermore, the attitudes of public funders towards the
use of ADs have not been formally explored, and little
focus has been directed to confirmatory trials in the UK
setting. To address these gaps in previous research, we
undertook multi-disciplinary and cross-sector in-depth
interviews of key stakeholders in clinical trials research
to inform the design of subsequent surveys [12]. Inter-
views were undertaken with a range of researchers in-
cluding public funding panel chairs and members,
statisticians, leaders of UK Clinical Trials Units (CTUs),
chief investigators, regulators, health economists, and
data monitoring committee members.
Based upon themes generated from the interview find-
ings [12], we conducted quantitative surveys aimed at
public and private sector researchers, and public fun-
ders, predominantly in the UK. The main objectives of
the surveys were as follows:
1. Investigate perceived barriers to and concerns re-
garding the use of ADs in confirmatory trials and gauge
the opinions of key stakeholders, such as public
funders;
2. Rank the barriers and concerns in order of per-
ceived importance for prioritisation and compare and
contrast these rankings between public and private sec-
tor researchers;
3. Investigate the types of ADs being implemented in
practice in confirmatory trials; and
4. With a focus on publicly funded trials, explore
ways to address perceived barriers and concerns and
propose recommendations in cases where ADs may
potentially offer added benefits to standard trial
designs.
Methods
Between November 2014 and January 2015, we con-
ducted three cross-sectional, parallel, quantitative online
surveys tailored for UK CTUs, private sector organisa-
tions, and public funders, exploring perceptions towards
and potential facilitators to the appropriate use of ADs
in confirmatory trials.
Surveys’ sampling frames
This research paid attention to researchers both in the
private and public sector as a collaborative platform for
addressing cross-sector roadblocks to the appropriate
use of ADs. In addition, the conduct of clinical trials re-
search and approval of effective and safe healthcare in-
terventions into medical practice is a complex process
involving various key stakeholders, such as funders/
sponsors, researchers and policymakers. Hence, pro-
spective participants were identified as follows:
The United Kingdom Clinical Research Collaboration
(UK CRC) comprises a network of registered CTUs with
expertise to coordinate and support high quality conduct
of clinical trials [13]. Consequently, major UK public
funders such as the National Institute for Health Re-
search (NIHR) and the Medical Research Council
(MRC) require, as part of their funding policy, the in-
volvement of UK CRC-registered CTUs with the vision
to improve quality in the conduct and delivery of pub-
licly funded clinical trials. Overall, there were 55 regis-
tered CTUs (2013/2014) across the UK [13], which we
contacted to take part in our research.
The NIHR is one of the major UK public funders of
medical research, contributing about a third of total re-
search funding – spending over £1 billion in 2013/2014
[14]. Within the NIHR programme, the Health Technol-
ogy Assessment (HTA) is the largest funding stream for
the commissioning of independent research, which in-
cludes predominantly confirmatory trials to assess clin-
ical and cost effectiveness, and the broader impact of
healthcare interventions that have been tailored for the
National Health Service (NHS) [15]. The HTA
programme has four boards supported by five advisory
panels and a priority group, some of whose members are
publicly contactable [16]. There are other NIHR funding
streams supporting a smaller proportion of confirmatory
trials, such as the Efficacy Mechanism and Evaluation
(EME), and Research for Patient Benefit (RfPB). In ac-
knowledging the crucial role of charity funders in clin-
ical trials research and to capture diverse views, Cancer
Research UK (CR UK) advisory panel members were
also contacted because it is one of the largest UK char-
ities funding confirmatory trials. In addition, huge op-
portunities to use adaptive designs are perceived in
therapeutic areas such as oncology [12]. We also
approached a second large UK charity funder, but
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unfortunately, the coordinating team was uncomfortable
about us contacting their boards and panel members.
Overall, 212 contactable public funding board members
and advisory panel members from HTA (n = 110), EME
(n = 20), RfPB (n = 40), and CR UK (n = 42) were
approached to take part.
Private sector trials research is mostly conducted by
pharmaceutical and biotech companies, and Contract Re-
search Organisations (CROs). Twenty-five companies with
which we had direct contact were approached to take part:
pharmaceutical or biotech organisations (n = 13) and
CROs (n = 12).
Design of survey instruments
A list of themes on perceived barriers, concerns, and poten-
tial facilitators was compiled based on prior findings from
our in-depth interview study [12]. These themes were then
grouped to develop survey instruments depending on to
whom they pertained: public funders, UK CTUs, and pri-
vate sector. Most of the questions were of a closed form;
however, we included open-ended questions for respon-
dents to add detailed responses where applicable. We
accessed the perceptions of respondents on the importance
of barriers and concerns towards, and usefulness of, poten-
tial facilitators to the appropriate use of ADs in confirma-
tory trials using widely accepted Likert Scales [17]. Most
questions for the UK CTU and private sector surveys were
phrased consistently, except on those occasions when spe-
cific questions were unique to a certain sector. Instruments
were internally reviewed and piloted prior to the launch of
the online surveys. Figure 1 displays a snapshot of CTU-
specific questions on barriers.
Approaching targeted participants
The Directors or designated Senior Statisticians were
contacted to complete the online survey instrument tai-
lored for UK CTUs. Only one response per CTU repre-
sentative was permitted. Two rounds of email invitations
with an information sheet were sent through the UK
CRC-registered CTU network of Directors and Senior
Statistician representatives. A third round of persona-
lised emails were directly sent to some non-responders
(n = 21) of the previous two rounds.
Public funding boards and panels chairs and ordinary
and lay members were approached through email to
complete an online survey tailored for public funders.
One round of invitation emails was sent to panel chairs
and vice chairs, and some panel members through the
NIHR programme coordinators. Some members were
directly contacted by personalised emails using online,
publicly accessible contact details.
For the private sector; two rounds of emails were dir-
ectly sent to trial Research Leaders or designated Princi-
pal or Senior Statisticians from 25 organisations with
whom we had contact. Multiple responses from the or-
ganisations with several trial research groups were per-
mitted where applicable.
All cross-sector participants were given between 3 and
8 weeks to complete the online surveys.
Statistical analysis and reporting
Descriptive statistics were generated, aided by forest
plots and clustered bar charts to display respondent per-
ceptions. A Rating Scale Model for ordered response
items [18] was employed to rank the perceived
Fig. 1 A snapshot of the UK CTUs survey instrument
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importance of barriers and concerns as characterised by
the ‘difficulty’ parameter using the RUMM2030 software
[19]. A respondent’s log odds of choosing a higher cat-
egory of an item on an importance (or concern) scale
over the previous adjacent category was modelled as a
function of the ability of the respondents, perceived level
of importance (or concern) attached to an item, and
threshold parameters of items as follows [18]:
ln
pnik
pniðk−1Þ
 !
¼ θn−ðδi þ τkÞ;
where pnik is the probability of a respondent n with abil-
ity θn choosing category k for an item i; k = 0,1,2,…; m
represents the ordered choices, and m is the number of
item steps; δi is the ‘difficulty’ of item i, which is the im-
portance location parameter of interest; τk is the thresh-
old parameter corresponding to choice k in item i; and
θn and τk are nuisance parameters.
The research utilised a recent review of existing guid-
ance on the reporting of survey research and attempted
to use relevant items to enhance its reporting [20]. To
facilitate interpretation and consistency, barriers and
concerns to the use of ADs are presented in order of
perceived importance. Proportions of item responses,
estimates of the importance parameters with associated
95 % confidence intervals (CIs), and item rank are
presented.
Ethical approval
This study received favourable ethical approval (0676)
from the School of Health and Related Research
(ScHARR) Ethics Committee at the University of
Sheffield. Participants were only permitted to complete
the survey after consenting, which was the opening
question on all survey instruments.
Results
Response rates
We observed a UK CTU crude response rate of 55 %
(30/55). In addition, 46 % (25/55) of respondents com-
pleted all key questions (barriers, concerns, and potential
facilitators). Approximately 68 % (17/25) of the organisa-
tions responded to the private sector survey. Of these,
52 % (13/25) responded to all key survey questions. Ap-
proximately 41 % (86/212) of the respondents completed
the online survey tailored for public funders. However,
the response rate to all key questions was around 30 %
(64/212). Non-response feedback from two UK CTUs
and six public funders cited a lack of basic understand-
ing of ADs to meaningfully contribute to the survey as
the main reason for non-participation.
Baseline characteristics of respondents
Of the 30 UK CTUs respondents, 10(33 %) and 18(60 %)
were Directors and Senior Statisticians respectively, and
two did not state their role. CTUs covered a wide geo-
graphical area across the UK and represented many
therapeutic areas of clinical trials research. Overlapping
and diverse therapeutic areas of research include oncol-
ogy (n = 13), mental health (n = 11), primary care (n = 9),
public health (n = 9), musculoskeletal (n = 8), respiratory
(n = 8), cardiovascular (n = 7), diabetes (n = 7), health
services (n = 7), emergency medicine (n = 6), infectious
(n = 2), rare or orphan diseases (n = 2), perinatal medi-
cine (n = 1), surgical interventions (n = 1), and other
(n = 3). Figure 2 displays the approximate distribution
of the study interventions as a percentage of the total
number of trials based on complete data reported. In
addition, the distribution of the trials requiring regula-
tory approval (such as from the MHRA, EMA, or
FDA) beyond standard ethics had a median (IQR) of
50 % (16 % to 80 %), based on 23 complete responses.
The expertise of public funder respondents in clinical
trials research was diverse and overlapping, representing
the composition of public funding boards and advisory
panels. These included trial statisticians 11(13 %), chief
investigators 40(47 %), trial methodologists 20(23 %),
trial management experts 6(7 %), clinical experts 23(27 %),
health economists 9(10 %), Independent Data Monitoring
Committee 33(38 %) and Trial Steering Committee
members 24(28 %), CTU directors 12(14 %), patient
representatives 7(8 %), and other 6(7 %). Ordinary
members and Chairs or Vice Chairs of boards or panels
constituted 63(73 %) and 10(12 %), respectively. Most
members (65 %) had served for less than 5 years on their
current funding boards or panels. Of the 17 industry re-
spondents, 9(56 %) and 7(44 %) were from pharmaceut-
ical or biotech organisations and CROs, respectively,
and one did not state the nature of their organisation.
Private sector respondents were predominantly Lead
Statisticians in the UK 13(81 %).
UK CTU perceptions of barriers to ADs use in
confirmatory trials
The distribution of respondents’ opinions and rank of
barriers, based on estimates of the perceived relative im-
portance parameters with associated 95 % CIs, from the
Rating Scale Model are displayed in Fig. 3. The more
negative or smaller the relative importance parameter,
the more important respondents perceived the barrier.
Supplementary summary data with detailed description
of survey questions relating to the barrier items pre-
sented in Fig. 3 are provided (see Additional file 1).
The lack of bridge funding accessible to CTUs to sup-
port the design work of complex and time-consuming
ADs was perceived as the top-ranked obstacle impeding
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the routine use of Ads and was reported by 8(32 %) and
12(48 %) respondents as an ‘extremely’ or and ‘at least
moderately’ important barrier, respectively. The lack of
practical implementation knowledge and hands-on ex-
perience was the second highest ranked barrier, with
6(24 %) ‘extremely’ and 15(60 %) ‘at least moderately’
important rankings. The opinions of respondents sug-
gested that research teams within the UK CTUs have a
strong preference for traditional mainstream designs
which they know well and feel uncomfortable supporting
Fig. 2 The distribution of the nature of interventions investigated by UK Clinical Trials Unit (CTU) respondents
Fig. 3 Ranked perceptions of UK Clinical Trials Units (CTUs) on the importance of barriers to adaptive designs (ADs) use in confirmatory trials
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ADs even when they are appropriate. Only 3(12 %) re-
spondents did not view it as an important barrier,
whereas 6(24 %) and 12(48 %) respondents reported it as
an ‘extremely’ and ‘at least moderately’ important barrier,
respectively (see Additional file 1).
Thirteen (52 %) respondents reported difficulties faced
by trialists in marketing ADs to key stakeholders in trials
research, such as clinical collaborators, funders, and reg-
ulators as ‘at least a moderately’ important barrier. The
amount of time and effort required to support the design
of ADs, and the time constraints relative to competing
priorities of the traditional mainstream designs was re-
ported as ‘at least an important’ barrier by 12(48 %) re-
spondents. The lack of applied training and insufficient
access to case studies on ADs to facilitate practical
learning and implementation were reported among the
top-ranked barriers. Statistical complexities such as sim-
ulations work as part of design, practical implementation
complexities and difficulties faced by clinical trialists in
setting up acceptable planned decision-making criteria
to guide the adaptation were among some of the
middle-ranked barriers.
Barriers reported as ‘not at all’ important by many re-
spondents were negative experiences based on funders’
or reviewers’ comments (76 %), negative implementation
experiences (76 %), early stopping decision-making ten-
sions among key decision-makers (60 %), and lack of
awareness of benefits of ADs (48 %).
UK public funder perceptions on barriers to the use of
ADs in confirmatory trials
Public funder respondents ranked the importance of
most barriers considered with a small degree of differen-
tiation (Fig. 4). Supplementary summary data with de-
tailed description of survey questions relating to barrier
items presented in Fig. 4 are provided (see Additional
file 2). The preference of public funders for traditional
mainstream designs over ADs and their risk-averse atti-
tude to fund projects associated with a high degree of fi-
nancial uncertainty were among the most important
barriers reported. Researchers’ inadequate description of
the rationale for using an AD and decision criteria to
guide the AD in grant proposals were reported as ‘at
least moderately’ important barriers by 60 % and 53 % of
respondents, respectively, thus making the review
process challenging. The dearth of expert proposal re-
viewers to provide advisory support to funders during their
grant commissioning process was selected by 32(55 %) and
11(19 %) of respondents, as a ‘moderately’ or ‘extremely’
important barrier, respectively. Inadequate descriptions
by the researchers of the proposed ADs and the scope
of these descriptions in the grant applications were also
ranked among the top-ranked barriers. Some of the
middle-ranked barriers were lack of commissioning
experience of AD-related research, and lack of aware-
ness of acceptable scope of ADs and when they are
appropriate in the confirmatory setting.
Fig. 4 Ranked perceptions of UK public funders on the importance of barriers to adaptive designs (ADs) use in confirmatory trials
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Challenges faced by funders in drawing up contractual
agreements that are suitable to support ADs were re-
ported by 38 % and 10 % of respondents to be a ‘moder-
ately’ or ‘extremely’ important barrier. The lowest
ranked of the perceived barriers were early trial stopping
decision-making tensions among key decision-makers
and negative attitudes towards ADs by some of the fund-
ing boards and panel members.
Private sector perceptions of barriers to the use of ADs in
confirmatory trials
In general, the perceptions of UK CTUs and the private
sector on the importance of different barriers are consist-
ent; however, there are a few exceptions (Figs. 3 and 5).
For instance, complexities during practical implementa-
tion, inadequate data management infrastructure, and fear
of risking regulatory approval appear to be very prominent
in the private sector (marked in red diamonds on Fig. 5).
In contrast, the lack of bridge funding to support develop-
mental design work and worry about research staff em-
ployment contracts when trials are stopped early were
highly and middle rated in the public sector, respectively
(marked in blue squares on Fig. 5). The top-ranked bar-
riers reported to be ‘at least moderately’ important were as
follows (see Additional file 3): the dearth of practical im-
plementation knowledge 9(69 %); time constraints to sup-
port the planning of complex ADs relative to competing
priorities of traditional mainstream designs 6(46 %);
associated practical complexities during implementation
of ADs 9(69 %); inadequate data management infrastruc-
ture for timely data capturing, cleaning, and processing to
support ADs 5(42 %); the dearth of applied training to fa-
cilitate practical implementation 9(69 %) and lack of
hands-on practical experience 8(62 %); limited access to
case studies of the few ADs that have been implemented
to facilitate practical learning 6(46 %); and research teams
being more comfortable with traditional mainstream de-
signs 8(62 %).
The middle ranked important barriers reported with
little degree of separation between them were the lack of
awareness of acceptable scope of ADs in confirmatory
trials; enormous amount of time and effort required dur-
ing planning; fear of regulatory reluctance and risk of
jeopardising chances of approval; difficulties faced in
marketing ADs to key stakeholders; the lack of aware-
ness of when ADs are appropriate; and difficulties faced
in setting up upfront, acceptable decision-making cri-
teria to guide trial adaptation (Fig. 5, Additional file 3).
Barriers reported as unimportant by a sizable number
of respondents were a lack of awareness of implementa-
tion resources 6(46 %), lack of knowledge of existing
AD-related statistical software 6(46 %), lack of motiv-
ational support from Research and Development (R & D)
6(46 %), negative regulatory experiences 5(38 %), lack of
expertise to support planning 5(38 %), costing complex-
ities during planning 6(46 %), negative experiences during
Fig. 5 Ranked perceptions of the private sector organisations on important barriers to adaptive designs (ADs) use in confirmatory trials. Red
diamonds indicate barriers that were ranked higher by the private sector than UK Clinical Trials Units (CTUs). Blue squares indicate barriers that
were ranked higher by the UK CTUs than the private sector
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implementation 7(54 %), insufficient R & D financial sup-
port to invest in AD infrastructure 8(62 %), the dearth of
statistical expertise to support ADs 8(62 %), and worry
about staff employment contracts when trials are stopped
early 10(77 %).
Cross-sector perceived concerns about the use of ADs in
confirmatory trials
The early stopping of trials (or treatment arms) for
futility - as soon as there is sufficient evidence of no
benefit - was the least ranked concern across sectors
(see Additional file 4). Concerns about the robustness
of ADs in decision-making and the acceptability of
findings to change medical practice when trials are
stopped early appeared more pronounced among pub-
lic funder respondents. The early stopping of trials
for efficacy or non-inferiority were top-ranked con-
cerns reported by UK CTUs and private sector
respondents, respectively. The fear of introducing op-
erational bias, impact of ADs on other important
study objectives (such as safety and health economic
evaluation) when trials are stopped early, and the po-
tential of population drift as a result of the AD and
its implications on the interpretation of findings were
viewed with varying degrees of concern among cross-
sector respondents. Supplementary summary data on
cross-sector concerns about the use of ADs in con-
firmatory trials and detailed description of survey
questions are provided (see Additional file 4).
Organisational priority to the use of ADs in confirmatory
trials
When respondents were asked to rate the level of organ-
isational priority they give to the use of ADs and/or re-
search on ADs–related methods within the next 5 to 10
years, 15(50 %) of the UK CTUs selected it as a ‘medium
priority’ and just 3(10 %) as a ‘high priority’. In contrast;
5(29 %), 4(24 %) and 4(24 %) private organisations se-
lected it as a ‘medium priority’, ‘high priority’, and an
‘essential priority’, respectively.
Only 2(7 %) UK CTUs and 3(18 %) of private sector
organisations reported having an AD-related Working
Group within their organisation. The willingness to ‘def-
initely consider’ the use of ADs in future confirmatory
trials, when appropriate, was expressed among 16(53 %)
UK CTUs and 11(65 %) private sector organisations.
Forty-five (55 %) of the public funder respondents
rated their boards or panels priorities on funding themes
on confirmatory ADs in the next 5 to 10 years as at least
a ‘medium priority’, 19(22 %) as ‘high priority’ and only
4(5 %) as an ‘essential priority’. As a funding board or
panel, only 26(30 %) reported that they had previously
recommended funding a confirmatory AD grant pro-
posal; however, 26(30 %) did not respond to the
question. When asked whether they would consider
recommending a confirmatory AD grant proposal for
funding in the future when appropriate to address re-
search question(s); 42(49 %) indicated that they ‘would
definitely consider’, 21(24 %) ‘might or might not con-
sider’, 1(1 %) ‘would not consider’, and 22(26 %) did not
respond to the question.
Potential facilitators to the appropriate use of ADs in
confirmatory trials
We found consistency in respondents’ perceptions
across sectors regarding the usefulness of potential facili-
tators to enhance the appropriate use of ADs. Figure 6
summarises the respondents’ opinions. The majority of
respondents reported that the availability of a trouble-
shooting toolkit of specific questions which clinical trial-
ists need to ask themselves when considering the
different types of ADs would be ‘somewhat useful’:
23(92 %) UK CTUs, 61(95 %) public funders, and 12(92 %)
private sector organisations. The overwhelming majority of
respondents reported that the access to published case
studies of implemented ADs focusing on aspects such as
design and rationale, implementation, regulatory and statis-
tical challenges; lessons learned; what went wrong; and
facilitators to challenges would be ‘very useful’ to re-
searchers. Twenty-three (92 %) CTUs and 57(89 %) of the
public funder respondents reported that the need for a con-
sensus guidance document on the acceptable scope of ADs,
which addressed issues tailored for publicly funded con-
firmatory trials, would be at least ‘somewhat useful’.
The existence of a CONSORT statement tailored for
ADs was selected as at least ‘somewhat useful’ to en-
hance transparency and completeness in the conduct
and reporting of ADs by 56(88 %) public funders, 23(92 %)
CTUs, and 13(100 %) private sector organisations. A
total of 46(72 %) of public funder respondents viewed
that refresher training of funding boards and panel
members to be familiar with AD-related issues could
help them in the reviewing and commissioning process.
Types of ADs implemented in confirmatory trials
The submission of historical AD-related grant proposals
for funding considerations was reported among 13(43 %)
of the UK CTUs. Historical use of at least some type of
AD in confirmatory trials was reported in 27 % (8/30) of
UK CTUs and 47 % (8/17) of the private sector organisa-
tions that responded to the surveys. Table 1 describes
the type and scope of ADs implemented in the public
and private sector. The use of ADs appears not to be
widespread across sector organisations; however, there
are a small number of pacesetter organisations fre-
quently using certain types of ADs as part of their re-
search development programs. The most commonly
used AD methods across the sector include sample size
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re-estimation (SSR), standard two-arm group sequential
design (GSD), futility analyses using stochastic curtail-
ment methods, and operational seamless 2/3 design.
Moreover, ADs with some form of futility stopping, such
as dropping futile treatment arms or stopping trials, ap-
peared popular, consistent with cross sector/disciplinary
receptiveness.
Discussion
We need to emphasise that ADs are not appropriate
for every trial. When contemplating the use of ADs,
logistical as well as statistical considerations should
be made on a trial-to-trial basis. These considerations
include the accrual of the primary endpoint data in
relation to the expected recruitment rate, the ration-
ale for choosing the design, feasibility or practicalities
of implementing the design in practice, and potential
benefits against additional complexities in implemen-
tation. Some of the considerations are highlighted in
our preceding research [12].
Main findings
Perceived barriers and concerns exist concerning the ap-
propriate use of ADs in the confirmatory setting for key
stakeholders in clinical trials research. Stakeholder per-
ceptions about barriers are largely consistent across sec-
tors, with a few exceptions that reflect differences in
organisational funding structures, experiences, and the
nature of study interventions. For example, the lack of
bridge funding accessible to UK CTUs in the form of
small grants to support design developmental work of
time-consuming and complex ADs was reported as the
major stumbling block to the routine use of ADs.
The most important cross-sector barriers appear to be
connected to the dearth of practical implementation
knowledge and experience, lack of applied training, and
paucity of implemented case studies of ADs to facilitate
practical learning and problem-solving. This is inter-
twined with the amount of time and effort required in
the planning of ADs. Moreover, both the private sector
and UK CTUs voiced concerns that they are under im-
mense pressure to deliver on other competing priorities
that are based on simpler traditional mainstream trial
designs. Hence, they have limited time to support com-
plex ADs, even when they are appropriate.
Implications for practice
There is cross-sector and multidisciplinary interest in
the use of ADs when appropriate to answer research
questions. The benefits of ADs can only be reaped when
key barriers to their use are adequately addressed.
First, there seems to be a strong need on the part of
public funders to address sources of funding accessible
to UK CTUs wishing to support the use of relevant,
complex, and time-consuming ADs. For instance, the
MAMS design requires in-depth statistical simulations
and time commitment. This developmental stage is often
unfunded, with researchers taking risks betting on
Fig. 6 Cross-sector perceptions of potential facilitators to the use of adaptive designs (ADs) in confirmatory trials. Denominators: public funders
(n = 64), UK Clinical Trials Units (CTUs) (n = 25), and private sector organisations (n = 13)
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uncertain future success of research grants. Hence, given
the high risk involved, UK CTUs may be reluctant to
support such ADs, even when they are more relevant to
answer research questions efficiently. Although in the
UK, the NIHR provides infrastructure funding accessible
to accredited CTUs [21], this funding is often used for
other purposes, such as meeting contractual obligations
of staff who may not receive funding between studies.
There is an opportunity for the NIHR and MRC to cre-
ate a small funding stream to support the design of
time-consuming designs provided the research questions
meet their priority needs, and there is a strong design
rationale. The funding should be conditional on open
access publication of design-related material such as
software programs to enhance planning of related future
trials. We would also encourage the use of ADs, which
are simple to implement within the existing scope of
public funding models for fixed sample size designs,
such as sample size reviews and futility assessments.
Most of the important barriers reported here are as-
sociated with a lack of practical knowledge and experi-
ence among key stakeholders. Numerous theoretical
Table 1 Distribution of the type of adaptive designs (ADs) implemented in confirmatory trials and their frequency stratified by
sector
Type of AD and its description UK Clinical Trials Units (CTUs) Private sector
Number of
CTUs
Number of
trials
Missing
responses
Number of
organisations
Number of
trials
Missing
responses
Sample size re-estimation (SSR) 7(23 %) 7(41 %)
Blinded SSR allowing for increase only 4 4 1 2 11 -
Blinded SSR allowing for increase or decrease 2 1 1 2 3 -
Unblinded SSR allowing for increase only 2 5 1 2 10 -
Unblinded SSR allowing for increase or decrease 2 5 1 - - -
Unblinded SSR based on promising zone concept 2 - 2 3 10 -
Standard two-arm Group Sequential Design (GSD) 7(23 %) 8(47 %)
Stopping early for futility only 2 7 1 3 26 -
Stopping early for efficacy only 1 . 1 - - -
Stopping early for efficacy or futility 4 6 - 3 8 1
Stopping early for safety only 4 2 2 2 5 1
Stopping early for safety or futility 2 2 - 1 5 -
Stopping early for non-inferiority only - - - 1 - 1
Futility analysis (outside GSD framework) 8(27 %) 5(29 %)
Based on conditional power 5 7 1 3 3 2
Based on predictive power 2 1 1 1 - 1
Based on confidence interval of the interim effect 3 3 1 - - -
Operational seamless 2/3 design 7(23 %) 6(35 %)
Dropping futile treatment arms in phase 2 only 5 5 1 3 3 1
Selecting only one promising treatment in phase 2 only 1 - 1 3 2 1
Selecting multiple promising treatments in phase 2 only - - - 2 3 1
Other 2 - 2 - - -
Inferential seamless 2/3 design 2(7 %) 3(18 %)
Dropping futile treatment arms in phase 2 only 2 1 1 1 2 -
Addition or dropping futile treatment arms in phase 2 only 1 . 1 - - -
Strictly phase 3 multi-arm multi-stage design 2(7 %) 2(17 %)
Stopping trial for efficacy or futility or dropping futile treatment arms 1 1 - - - -
Information-based GSD - - - 4(24 %) 3 2
Standard GSD with SSR - - - 1(6 %) - 1
Patient enrichment or subgroup selection 2 (7 %) . 2 2(12 %) - 2
Response adaptive randomisation 2(7 %) 2 - 2(12 %) 2 1
Note: Denominator is based on responders; UK CTUs (n = 30) and private sector organisations (n = 17)
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developments have occurred in ADs, and more are
needed to address unknowns. However, what is lacking
is a translational framework to enhance the use of the
ADs in practice. We encourage accessible publication
of case studies of successful and unsuccessful ADs
with related materials. These publications should en-
compass aspects such as rationale and design; statis-
tical and practical challenges, and how they are
resolved; implementation resources; lessons learned;
regulatory, data management and communication hur-
dles, and how these are resolved; and other facilitators
to successful implementation. Learning from re-
searchers or organisations who are routinely imple-
menting ADs is paramount. Most importantly, a need
exists for a focal group of practical experts who are
publicly funded to support those CTUs with little
practical expertise wishing to implement ADs. Fur-
thermore, such experts should provide practical train-
ing accessible on ADs to UK CTUs. Although an
initiative exists through the MRC Hubs for Trials
Methodology Research Network AD Working Group
[22], some trialists viewed it as being more theoretic-
ally oriented [12]. Most importantly, it seems that the
time is upon us for close collaboration in the practical
implementation of ADs.
We strongly encourage researchers who receive public
funding for AD-related methodological research to pro-
duce open access resources such as free-to-use software
or code to implement the methods developed. This
would facilitate the application of the methods. A rec-
ommendation also is that CTUs receiving AD-related
bridge or research funding should form a compendium
of case studies for publication. Open-access publication
of research outputs and resources such as in mono-
graphs is important. This could be an important re-
source aimed at reducing research waste and improving
the appropriate conduct of adaptive trials. Such
knowledge-sharing would be helpful for applied know-
ledge transfer.
Concerns regarding the robustness of ADs in decision-
making and their credibility to change practice when tri-
als are stopped early are real and should be addressed.
Even though there are multi-dimensional aspects to
these concerns, transparent and adequate reporting of
trial conduct may alleviate some of the concerns. For in-
stance, suboptimal reporting of appropriate statistical
methods to obtain unbiased trial results (point estimates,
CIs and P-values) following an AD may influence con-
sumers of research findings to view them with suspicion
[23–25]. There is a need for a CONSORT statement tai-
lored for ADs to enhance their reporting and conduct.
We support recent related initiatives proposing some
adaptive trial aspects, which should be reported by re-
searchers [26]. Case studies of ADs investigating a wide
range of interventions published in ‘high impact’ jour-
nals and their influence on clinical practice could also
help to convince sceptical research consumers.
Like any new methods, the use of ADs in confirmatory
trials is bound to raise anxiety among some researchers.
Some of this anxiety could be alleviated by a cross-
disciplinary, consensus guidance document on ADs well-
crafted to addressing pertinent issues in confirmatory
trials. For instance, the design of complex interventions
has gone through a similar phase, but the emergence of
related guidance documents improved researchers’ recep-
tiveness towards their conduct [27]. Most importantly,
there is a need for a troubleshooting toolkit with pertinent
design-specific questions, which trialists need to ask them-
selves when considering ADs. This could be helpful in the
appropriate planning of ADs.
Optimal description of any proposed AD by re-
searchers to key stakeholders (reviewers, funders/spon-
sors, collaborators and regulators) where appropriate is
fundamental; its rationale within the context of the re-
search objectives, potential benefits compared to main-
stream traditional approach, scope, decision criteria to
guide the adaptation and decision-making process, vari-
able costs and trial durations, measures to minimise op-
erational bias and control of statistical properties (type I
error rate, power and inference), among others should
be addressed. For instance, our preceding research [12]
found that the fear of risking regulatory approval does
not necessarily reflect regulatory perspective but is
mostly an artefact of inadequate description of the pro-
posed AD and its suitability to address the research
question(s). There are encouraging indications that regu-
latory receptiveness to the appropriate use of ADs is
positive, with improving awareness and experiences, par-
ticularly with respect to scientific advice and review of
AD proposals [5, 12, 28, 29]. In this regard, as reflected
in our preceding research [12], we encourage funders to
modify their grant application forms to facilitate ad-
equate description of AD-related aspects. This could be
achieved by allowing clinical trialists to add specific
relevant AD material as appendices.
Periodic ‘refresher training’ of public funding boards
and panel members prior to their commissioning meet-
ing may help alleviate a lack of awareness of the accept-
able scope of ADs, when they are appropriate, and their
benefits in confirmatory trials. We believe the experience
of funding boards and panels can only be improved
when researchers put forward more appropriate AD-
related grant proposals for consideration. A positive
change in attitudes and receptiveness towards appropri-
ate use of ADs by public funders is an encouraging op-
portunity, which should be exploited by researchers.
The challenges faced by researchers in developing
widely-acceptable decision-making criteria at the design
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stage to inform the adaptation process can be alleviated
through multidisciplinary engagement and discussions
during planning. This process should include close dis-
cussions among key stakeholders such as trial statisti-
cians, clinicians, patient representatives, clinical peer
advocate groups, and regulators. Our preceding study
summarises some additional facilitators to the appropri-
ate use of ADs [12].
Interpretation of the findings
This study is based on themes generated from cross-
sector and cross disciplinary in-depth interviews of key
stakeholders involved in clinical trials research. Notably,
the surveys explored the perceptions of funders and tri-
alists towards ADs, predominantly in the UK confirma-
tory setting. Most importantly, this is the first study that
employed Rating Scale Modelling to rank barriers in
order of perceived importance to address the research
question.
Some of our findings on barriers are consistent with
the literature [4, 6, 9, 11]. The most top-rated barriers,
such as lack of practical knowledge, lack of applied
training, time constraints to support planning, research
teams preferring traditional mainstream designs to ADs,
and limited access to case studies about ADs to facilitate
practical training were reported in both the private and
public sectors. In contrast, some barriers such as inad-
equate data management infrastructure to support ADs
and associated practical complexities during planning
were viewed by private sector organisations as more im-
portant than in the public sector. This could be partly
explained by differences in experiences in the conduct of
ADs – hence, a differential awareness of the practical
challenges faced. This could also be due to the differ-
ences in the type of interventions under investigation
and the regulatory framework.
It should be noted that our findings are based on
moderate response rates across sectors. Most recent sur-
veys of UK CTUs observed response rates of 38 % [30]
and ranged from 25 % to 67 % [31]. The private sector
organisations we had contact with were invited to take
part. The number of responders was similar to previous
research by the AD Working Group (USA) although
they achieved a 100 % questionnaire response rate over
a 1-year period [6]. To the best of our knowledge, we
are not aware of previous research surveying public fun-
ders. Bearing all this in mind and based on email replies
from non-responders (UK CTUs and public funders),
the non-responders are likely different from the re-
sponders. For instance, non-responders seem more likely
to be unfamiliar with ADs or do not view ADs as a pri-
ority. Hence, some of our findings on barriers, such as
awareness of ADs, their benefits and acceptable scope in
confirmatory setting, and lack of statistical expertise
highlighted during interviews [12], could be underesti-
mated. On the other hand, one could argue that such
findings are conservative.
Conclusions
A general multi-disciplinary and cross-sector interest ex-
ists for the appropriate use of ADs. However, there are
still persistent and important perceptions of organisa-
tional and individual roadblocks hampering the appro-
priate uptake of ADs in clinical trial practice. The lack
of bridge funding accessible to UK CTUs wishing to
support developmental design work seems to be an im-
portant obstacle requiring redress. A cross-sector collab-
oration and paradigm shift towards translational applied
training, and accessible publication of case studies on
ADs are paramount in addressing the dearth of know-
ledge and experience. Most importantly, a troubleshoot-
ing toolkit of key design-specific questions researchers
need to ask themselves when considering ADs, transpar-
ent and adequate reporting of the conduct of adaptive
trials, and a multidisciplinary consensus guidance docu-
ment on the acceptable scope of ADs in confirmatory
trials are all required to facilitate their appropriate use.
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